Fingolimoid is an effective oral treatment for MS.

The article presents two studies which explored the effectiveness of an orally administered fingolimod in treating multiple sclerosis (MS). The studies were conducted by Jeffrey Cohen of the Cleveland Clinic and Ludwig Kappos of the University of Basel, Switzerland. The first study compared two daily doses of fingolimod with interferonß1a while the other compared the same dose to a placebo. It was found out that there was no significant difference in the efficacy between the two fingolimod doses.